Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 132
Filter
1.
J Laparoendosc Adv Surg Tech A ; 30(1): 6-11, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31573396

ABSTRACT

Background: With the creation of a new bariatric center in Abu Dhabi, United Arab Emirates (UAE) and the organization of this bariatric department according to the international guidelines, a new activity of bariatric surgery started in January 2015. The surgeon had 20 years of experience in this field and he had performed over 5000 major laparoscopic bariatric procedures before starting this new bariatric program. The concept of enhanced recovery after bariatric surgery (ERABS) was applied from the beginning of the program. We decided to analyze the first 2 years of ERAS activity after having split them in two different periods: the 1st year of activity included restrictive procedures and the 2nd year associated malabsorptive surgeries. Materials and Methods: The results of the use of a fast-track program could be measured by different parameters like operative time, length of hospital stay, rate of complications, and rate of readmission and reoperation. Results: Between January and December 2015, 116 patients underwent a bariatric procedure. The mean age was 34.6 years (16-61) and average body mass index (BMI) was 41.7 kg/sqm (32-72.2). Sixty percent of patients were women and 37% of patients had at least one comorbidity (diabetes type 2, high blood pressure, hyperlipidemia, or sleep apnea). Ninety-four percent of the procedures were laparoscopic sleeve gastrectomy (LSG), 2.6% were laparoscopic Roux-en-Y gastric bypass, and 3.4% band removal. The mean operative time was 20 minutes for an LSG (14-45 minutes) and the average hospital stay was 1.2 days (standard deviation [SD]: 0.9-3.3). The rate of complications was 1.7% with 1 postoperative hematoma drained by CT scan on day 14 after the surgery and 1 relative stenosis endoscopically dilated on postoperative day 45. No reoperation was done. No leak was observed. At 1 year, the mean excess weight loss (EWL) was 64% (47-124) in 89 patients with a 76% rate of follow-up. For the 2nd year of activity in 2016, 142 patients went in the program. The mean age was 32.7 years (17-64) and average BMI was 42.3 kg/sqm (31-68). Seventy-two percent were women and 41% of the patients had one comorbidity or more. The majority of surgeries performed were LSG for 83.1% of the patients. RYGB was realized in 4.2% of cases, resleeve gastrectomy in 4.2%, and band removal in 1.4%. Some malabsorptive surgeries were performed as well, such as one anastomosis gastric bypass for 3 patients (4.2%), and single anastomosis duodeno-ilelal in 2 cases (2.8%). The average hospital stay was 1.5 days (SD: 0.9-3.5). No complication was observed. No reoperation was done. Two patients (1.4%) came back to the hospital on postoperative day 2 and 8 after a LSG for one or several episodes of vomiting without further complication. At 1 year, the mean EWL was 68% (49-154) in 98 patients with a 69% rate of follow-up. Conclusions: This new program of bariatric surgery in two steps using fast-track protocols, respecting international guidelines and with an experienced surgeon showed on its 1st year of implementation a 1.7% rate of readmission on 116 patients without reoperation or major complication and a hospital stay of 1.2 days. For the 2nd year of implementation with the inclusion of malabsorptive procedures only 2 patients (1.4%) were readmitted for a short episode of vomiting and the hospital stay was 1.5 days.


Subject(s)
Enhanced Recovery After Surgery , Gastrectomy , Gastric Bypass , Obesity, Morbid/surgery , Adolescent , Adult , Body Mass Index , Female , Gastrectomy/adverse effects , Gastrectomy/methods , Gastric Bypass/adverse effects , Gastric Bypass/methods , Humans , Laparoscopy , Length of Stay , Malabsorption Syndromes/surgery , Male , Middle Aged , Operative Time , Patient Readmission , Postoperative Period , Reoperation , Retrospective Studies , Treatment Outcome , Weight Loss , Young Adult
2.
Obes Surg ; 30(3): 804-811, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31863410

ABSTRACT

INTRODUCTION: Weight regain after laparoscopic Roux-en-Y gastric bypass (RYGB) occurs in up to 35% of patients. Revisional surgery may be applied. Conversion from RYGB to a long biliopancreatic limb (BPL) RYGB is a potential option for revisional surgery and short-term results are promising. METHODS: All patients who underwent conversion to long BPL RYGB due to weight loss failure, defined as excess weight loss (EWL) < 50% or body mass index (BMI) > 35 kg/m2, were assessed. Proximal RYGB or very very long limb RYGB (VVLL RYGB) was modified by shortening of the total alimentary limb length (TALL) to create a long BPL. RESULTS: A total of 28 patients received revisional surgery from either PRYGB (n = 22) or VVLL RYGB (n = 6). Mean age at operation was 45.3 ± 10.4 years, with 78% females. Mean prerevisional BMI was 41.7 ± 4.4 kg/m2. Mean time to revision was 76.5 ± 38.5 months. Limb lengths were 150 cm (95% CI 133-156 cm) for RL and 100 cm (95% CI 97-113 cm) for CC, thus providing a total median alimentary limb length of 250 (95% CI 238-260 cm). Additional %EWL and TWL improved significantly in long-term. Five years postoperatively, all patients (n = 9) had an EWL% > 50%. Six patients (21.4%) required reoperation due to severe malnutrition during the postoperative course. CONCLUSION: Conversion from RYGB to BPL RYGB leads to significant additional weight loss in the long term. However, the morbidity is relevant, especially severe protein malnutrition and the frequency of revisional surgery. Therefore, this type of surgery should not be done routinely.


Subject(s)
Biliopancreatic Diversion/methods , Duodenum/pathology , Gastric Bypass/adverse effects , Jejunum/pathology , Obesity, Morbid/surgery , Reoperation/methods , Adult , Biliopancreatic Diversion/adverse effects , Body Mass Index , Duodenum/surgery , Female , Follow-Up Studies , Gastric Bypass/methods , Humans , Jejunum/surgery , Laparoscopy/methods , Malabsorption Syndromes/epidemiology , Malabsorption Syndromes/surgery , Male , Middle Aged , Obesity, Morbid/epidemiology , Obesity, Morbid/pathology , Organ Size/physiology , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Postoperative Complications/surgery , Postoperative Period , Protein-Energy Malnutrition/epidemiology , Protein-Energy Malnutrition/surgery , Reoperation/adverse effects , Switzerland/epidemiology , Treatment Failure , Weight Gain/physiology , Weight Loss
3.
Gastroenterol Clin North Am ; 48(4): 575-583, 2019 12.
Article in English | MEDLINE | ID: mdl-31668184

ABSTRACT

"The intestinal transplantation is reserved for patients with life-threatening complications of permanent intestinal failure or underlying gastrointestinal disease. The choice of the allograft for a particular patient depends on several factors and the presence of concurrent organ failure, and availability of the donor organs, and specialized care. Combined liver and intestinal transplant allows for patients who have parenteral nutrition-associated liver disease a possibility of improved quality of life and nutrition as well as survival. Intestinal transplantation has made giant strides over the past few decades to the present era where current graft survivals are comparable with other solid organ transplants."


Subject(s)
Intestines/transplantation , Malabsorption Syndromes/surgery , Abdominal Wall/surgery , Allografts , Humans , Liver Transplantation , Parenteral Nutrition/adverse effects , Pseudomyxoma Peritonei/surgery , Quality of Life , Viscera/transplantation
4.
Obes Surg ; 29(2): 376-386, 2019 02.
Article in English | MEDLINE | ID: mdl-30251095

ABSTRACT

BACKGROUND: Management of failed laparoscopic gastric plication (LGP), defined as weight regain or inadequate weight loss, is a challenging issue. METHODS: This prospective investigation was conducted in individuals with morbid obesity who had undergone LGP from 2000 to 2016. Patients with weight loss failure, weight regain, and regain-prone cases were indicated for reoperation. Re-plication, laparoscopic one anastomosis gastric bypass (LOAGB), and modified jejunoileal bypass were done as revisional surgery. RESULTS: Revisional surgery was performed in 102 of 124 patients who needed reoperation. Overall, 39 re-plication, 38 LOAGB, and 25 malabsorptive procedures were performed. Re-plication was the shortest surgery and had the shortest length of hospital stay. The percentage of TWL at 6, 12, and 24 months of follow-up was 20.5%, 25%, and 26.8% for re-plication; 20.2%, 27%, and 30.5% for LOAGB; and 22.9%, 28.9%, and 32.6% for the malabsorptive procedure, respectively. In addition, the percentage of EWL at 6, 12, and 24 months of follow-up was 62%, 74.6%, and 79.6% for re-plication; 51.6%, 68.2%, and 75.9% for LOAGB; and 55.4%, 70.1%, and 79.1% for malabsorptive procedure, respectively. In long-term follow-up, according to %TWL, LOAGB and malabsorptive procedure had better outcome compared to re-plication, whereas there was no statistically significant difference in %EWL among the three surgical approaches. CONCLUSIONS: In terms of weight loss, reoperation on failed LGP was completely successful and no treatment failure was reported. All three revisional procedures, including re-plication, LOAGB, and malabsorptive procedure showed promising results and provided substantial weight loss. Since there is little information about the long-term efficacy and safety of revisional surgery on failed LGP, we highly recommend further investigations to confirm our results.


Subject(s)
Gastric Bypass/adverse effects , Laparoscopy/adverse effects , Obesity, Morbid/surgery , Postoperative Complications/surgery , Reoperation , Adult , Female , Gastric Bypass/methods , Gastric Bypass/statistics & numerical data , Humans , Jejunoileal Bypass/adverse effects , Jejunoileal Bypass/methods , Laparoscopy/methods , Laparoscopy/statistics & numerical data , Length of Stay/statistics & numerical data , Malabsorption Syndromes/epidemiology , Malabsorption Syndromes/etiology , Malabsorption Syndromes/surgery , Male , Middle Aged , Postoperative Complications/epidemiology , Prospective Studies , Reoperation/methods , Reoperation/statistics & numerical data , Retrospective Studies , Stomach/surgery , Treatment Failure , Weight Loss/physiology
5.
Liver Transpl ; 24(12): 1726-1735, 2018 12.
Article in English | MEDLINE | ID: mdl-30112820

ABSTRACT

Rejection is one of the most important drawbacks for graft and patient survival in intestinal and multivisceral transplantation. However, there is no consensus on the diagnostic criteria for humoral rejection, and the literature about the role of donor-specific antibodies (DSA) on allograft outcome and the risk factors that contribute to their development is scant with contradictory results. The present study analyzes the role of DSA exclusively in a pediatric cohort of 43 transplants. Among our patients, 11.6% showed preformed DSA, but they did not correlate with more rejection or less allograft survival. Having previous transplants was the main sensitization factor with an odds ratio (OR) = 44.85 (P = 0.001). In total, 16.3% of recipients developed de novo donor-specific antibodies (dnDSA), mostly directed against human leukocyte antigen (HLA) class II, polyspecific and complement fixing. Additionally, the presence of dnDSA had a deleterious effect on graft rejection (hazard ratio [HR] = 11.00; P = 0.01) and survival (HR = 66.52; P < 0.001) in an observational period of 5 years after transplantation. The inclusion of the liver emerged as the main protective factor against dnDSA development with an OR = 0.07 (P = 0.007). The analysis of HLA compatibility at the serological and epitope level with the computational tools HLAMatchmaker and PIRCHE revealed no association between HLA mismatching and dnDSA. In conclusion, this study performed in pediatric recipients shows the deleterious effect of dnDSA on intestinal transplantation supported by the complement-fixing activity observed. Additionally, the liver inclusion in the allografts showed to be a protective factor against dnDSA generation.


Subject(s)
Graft Rejection/immunology , HLA-D Antigens/immunology , Intestines/transplantation , Isoantibodies/immunology , Liver Transplantation/adverse effects , Malabsorption Syndromes/surgery , Adolescent , Allografts/immunology , Child , Child, Preschool , Female , Follow-Up Studies , Graft Survival/immunology , Histocompatibility Testing , Humans , Immunity, Humoral , Infant , Infant, Newborn , Liver/immunology , Liver Transplantation/methods , Male , Risk Factors , Transplantation, Homologous/adverse effects , Treatment Outcome
6.
Obes Surg ; 28(6): 1504-1510, 2018 06.
Article in English | MEDLINE | ID: mdl-29159553

ABSTRACT

BACKGROUND: This study aimed to evaluate the outcomes of 67 patients who underwent revisional bariatric surgeries over a 29-year period in a Brazilian public hospital. METHODS: The records of all patients who underwent revisional bariatric surgery from January 1987 to December of 2016 at our hospital were analyzed for weight loss and complications. Descriptive statistics and paired t tests were computed. RESULTS: Sixty-seven patients were included in the study. The primary surgeries previously performed on these patients were biliopancreatic diversion with duodenal switch (BPD-DS) (37 cases, 55.2%), jejunoileal bypass (JIB) (24 cases, 35.8%), sleeve gastrectomy (4 cases, 5.9%), Roux-en-Y gastric bypass (RYGB) (1 case, 1.5%), and laparoscopic adjustable gastric band (1 case, 1.5%). The indications for revisional surgery were as follows: malnutrition in 29 cases (43.3%), failure to lose weight in 27 cases (40.3%), weight regain in 5 cases (7.5%), and untreatable diarrhea in 6 cases (9.2%). Most revisional surgeries were performed using JIB or BPD-DS. Operative mortality was higher after the revisional procedures compared with that following the primary bariatric surgeries. CONCLUSIONS: Most patients requiring a revisional surgery had undergone a primary BPD-DS or JIB. Severe and untreatable malnutrition and diarrhea were the main indications for the revisional procedures. RYGB produced significant and sustainable weight loss and exhibited a low risk of malnutrition or requiring revisional surgery.


Subject(s)
Bariatric Surgery/adverse effects , Malabsorption Syndromes/surgery , Obesity, Morbid/surgery , Postoperative Complications/surgery , Reoperation , Adult , Bariatric Surgery/methods , Bariatric Surgery/statistics & numerical data , Biliopancreatic Diversion/adverse effects , Biliopancreatic Diversion/methods , Biliopancreatic Diversion/statistics & numerical data , Brazil/epidemiology , Comorbidity , Female , Follow-Up Studies , Gastrectomy/adverse effects , Gastrectomy/methods , Gastrectomy/statistics & numerical data , Gastric Bypass/adverse effects , Gastric Bypass/methods , Gastric Bypass/statistics & numerical data , Hospitals, Public , Humans , Jejunoileal Bypass/adverse effects , Jejunoileal Bypass/methods , Jejunoileal Bypass/statistics & numerical data , Laparoscopy/methods , Laparoscopy/statistics & numerical data , Malabsorption Syndromes/epidemiology , Malabsorption Syndromes/etiology , Male , Middle Aged , Mortality , Obesity, Morbid/epidemiology , Postoperative Complications/epidemiology , Reoperation/methods , Reoperation/mortality , Reoperation/statistics & numerical data , Retrospective Studies , Weight Loss
7.
Obes Surg ; 27(12): 3344-3348, 2017 12.
Article in English | MEDLINE | ID: mdl-28952026

ABSTRACT

BACKGROUND: Laparoscopic single anastomosis duodenoileal bypass with sleeve gastrectomy (SADI-S) is a recently developed one- or two-stage operation based on biliopancreatic diversion that is used to treat morbid obesity. Some midterm outcomes suggest that malabsorption is a possible complication following the procedure. Therefore, conversion to a less malabsorptive procedure may be required. We aim to describe and analyze the outcomes after laparoscopic conversion of SADI-S to non-malabsorptive or less malabsorptive procedures. METHODS: From January 2015 to April 2017, five patients underwent laparoscopic conversion to single anastomosis duodenojejunal bypass with sleeve gastrectomy (SADJ-S) (video) following SADI-S, and one female patient underwent laparoscopic conversion to gastric bypass (GBP) following SADI-S, after presenting with severe protein-calorie malnutrition, nutritional deficiencies, poor quality of life, or increased number of bowel movements. RESULTS: Mean preoperative BMI was 24.0 kg/m2 (20.4-27.5 kg/m2). Four patients underwent SADI-S to SADJ-S conversions and one underwent a SADI-S to Roux-en-Y duodenojejunal bypass. All cases were performed laparoscopically. No relevant postoperative complications or mortality was reported and the mean hospital stay was 4.6 days. Malabsorptive symptoms resolved in all patients. All patients experienced weight regain. Mean BMI increase was 7.1 kg/m2 (5-10.8 kg/m2). CONCLUSIONS: Outcomes of laparoscopic conversion to SADJ-S or GBP after SADI-S were acceptable, showing clinical improvement of malnutrition, nutritional deficiencies, and quality of life in all cases. Weight regain must be advised. These techniques appear feasible and free of severe long-term complications. Further investigation is warranted to understand the best common channel length for patients undergoing SADI-S.


Subject(s)
Gastrectomy/adverse effects , Gastric Bypass/adverse effects , Malabsorption Syndromes/etiology , Malabsorption Syndromes/surgery , Obesity, Morbid/surgery , Reoperation/methods , Adult , Biliopancreatic Diversion/methods , Duodenum/surgery , Female , Gastrectomy/methods , Gastric Bypass/methods , Humans , Laparoscopy/methods , Length of Stay , Male , Middle Aged , Obesity, Morbid/metabolism , Postoperative Complications/surgery , Quality of Life , Weight Loss
8.
Surg Obes Relat Dis ; 13(6): 988-994, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28223090

ABSTRACT

BACKGROUND: Omega-loop gastric bypass (OLGB) may be associated with severe complications, including anastomotic leak, refractory ulcer or stenosis, undernutrition, and disabling digestive disorders (chronic diarrhea, steatorrhea, bile reflux, and vomiting). OLGB conversion to Roux-en-Y gastric bypass (RYGB) was suggested to treat these complications. OBJECTIVES: To evaluate the efficacy and risk of severe complications after OLGB conversion to RYGB. SETTING: University hospital. METHODS: Retrospective analysis between October 2011 and June 2016. RESULTS: Seventeen patients underwent OLGB conversion to RYGB. Fourteen patients (82%) presented at least 1 disabling digestive disorder. Before conversion, 10 patients (58.8%) received nutritional support for undernutrition. There was no postoperative mortality. Seven patients (41.1%) developed major adverse events (<90 d). At conversion, the average weight, body mass index, and percent of excess weight loss for the population without undernutrition (n = 7) were 103.7±24 kg, 38.7±6.8 kg/m², and 37%±33%, respectively. These values were 85±18.3 kg, 30.6±4.7 kg/m², and 73.3%±21.5%, respectively, at 2 years. In patients with undernutrition (n = 10), the average weight, body mass index, and percent of excess weight loss were 52.2±16.5 kg, 18.7±5.9 kg/m², and 149.3%±46.5%, respectively, before nutritional support and 58.9±14.7 kg, 21.1±5.2 kg/m², and 132.7%±39.1%, respectively, at revisional surgery. At 2 years the values were 71±5.6 kg, 24.3±2.2 kg/m², and 104.6%±15.2%, respectively. The patients experienced significant improvements in hypoalbuminemia, anemia, and vitamin/trace element deficiencies. The disabling digestive disorders resolved in 85% of patients. CONCLUSION: The conversion of OLGB to RYGB for severe complications allows for weight correction in patients with undernutrition, reduces disabling digestive disorders, and improves the nutritional status of patients. However, the conversion is associated with high morbidity.


Subject(s)
Digestive System Diseases/etiology , Gastric Bypass/adverse effects , Laparoscopy/adverse effects , Adult , Anemia/etiology , Anemia/surgery , Digestive System Diseases/surgery , Female , Gastric Bypass/methods , Humans , Hypoalbuminemia/etiology , Hypoalbuminemia/surgery , Malabsorption Syndromes/etiology , Malabsorption Syndromes/surgery , Male , Malnutrition/etiology , Malnutrition/surgery , Nutrition Assessment , Postoperative Complications/etiology , Postoperative Complications/surgery , Reoperation/statistics & numerical data , Retrospective Studies , Surgical Stapling/statistics & numerical data , Treatment Outcome , Weight Gain/physiology , Weight Loss/physiology
9.
Cir Cir ; 85(2): 135-142, 2017.
Article in Spanish | MEDLINE | ID: mdl-27842762

ABSTRACT

BACKGROUND: Bariatric surgery continues to be the best treatment for weight loss and control of obesity related comorbidities. Gastric bypass and sleeve gastrectomy have demonstrated to be the most effective surgeries, but this has not been established in a Mexican (non-American) population. OBJECTIVE: To analyse the improvement in type 2 diabetes mellitus and carbohydrate intolerance in obese patients after bariatric surgery. MATERIAL AND METHODS: A retrospective analysis was performed on the data collected prospectively between 2013 and 2015 on every obese patient with diabetes and carbohydrate intolerance submitted for bariatric surgery. Analysis was performed at baseline, and at 1, 3, 6, 9 and 12 months, and included metabolic, clinical, lipid, and anthropometrical parameters. A peri-operative and morbidity and mortality analysis was also performed. Remission rates for patients with diabetes were also established. RESULTS: The analysis included 73 patients, 46 with diabetes and 27 with carbohydrate intolerance. Sixty-two patients were female with a mean age of 42 years. Baseline glucose and glycosylated haemoglobin were 123±34mg/dl and 6.8±1.6%, and at 12 months they were 90.1±8mg/dl and 5.4±0.3%, respectively. Diabetes remission was observed in 68.7% of patients, including 9.3% with partial remission and 21.8% with an improvement. There was also a significant improvement in all metabolic and non-metabolic parameters. CONCLUSIONS: Bariatric surgery safely improves the metabolic status of patients with diabetes mellitus or carbohydrate intolerance during the first year, inducing high rates of complete remission. It has also shown a significant improvement on blood pressure, lipid, and anthropometric parameters during the first year of follow-up.


Subject(s)
Bariatric Surgery , Carbohydrate Metabolism, Inborn Errors/surgery , Diabetes Mellitus, Type 2/surgery , Malabsorption Syndromes/surgery , Obesity/surgery , Adult , Carbohydrate Metabolism, Inborn Errors/complications , Cohort Studies , Diabetes Mellitus, Type 2/complications , Female , Humans , Malabsorption Syndromes/complications , Male , Mexico , Middle Aged , Obesity/complications , Retrospective Studies , Young Adult
10.
Acta Chir Belg ; 116(6): 333-339, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27477384

ABSTRACT

BACKGROUND: Microvillus inclusion disease (MVID) is a known congenital cause of intractable diarrhea resulting in permanent intestinal failure. There is need for a lifelong total parenteral nutrition (TPN) from diagnosis and the prognosis is poor. Most patients die by the second decade of life as a result of complications of parenteral alimentation including liver failure or sepsis. The only available treatment at this moment is a small bowel transplantation. But before that moment, the patients often suffer from a persistent failure to thrive and electrolyte disturbances despite continuous TPN. METHODS AND RESULTS: We report what we believe is a first case of an extensive small bowel resection in a 5-month-old boy with proven MVID to act as a bridge to (liver-) intestinal transplantation to treat failure to thrive and intractable diarrhea. CONCLUSIONS: An extensive small bowel resection can be done to enhance the chance of survival leading up to the transplantation by managing fluid and electrolyte imbalance. It facilitates medical management of these patients and makes a bowel transplantation possible at a later stage.


Subject(s)
Digestive System Surgical Procedures/methods , Intestines/surgery , Malabsorption Syndromes/surgery , Microvilli/pathology , Mucolipidoses/surgery , Organ Transplantation , Biopsy , Follow-Up Studies , Humans , Infant, Newborn , Intestines/diagnostic imaging , Malabsorption Syndromes/diagnosis , Male , Mucolipidoses/diagnosis , Time Factors
12.
Acta Gastroenterol Latinoam ; 45(1): 65-9, 2015 Mar.
Article in Spanish | MEDLINE | ID: mdl-26076517

ABSTRACT

Tufting enteropathy (TE), previously known as intestinal epithelial dysplasia, is a rare congenital enteropathy characterized by refractory diarrhea in the neonatal period. It presents clinical and histological heterogeneity and may be associated with birth defects and punctuate keratitis. The causative gene(s) have not yet been identfied making prenatal diagnosis unavailable. Although there are milder phenotypes most require parenteral nutrition for prolonged periods with the risk of complications. TE becomes an indication for intestinal transplantation. We report the case of a 4-month-old male, born full term with a normal weight. The parents consulted because of severe malnutrition and chronic watery diarrhea. Duodenal and rectal biopsy was negative. Because of poor tolerance gastroclysis was changed to parenteral nutrition. The infant had several catheter-related infections and died at 13 months from catheter-associated complications. Histopathological autopsy was performed. The material was fixed in paraffin and studied with routine techniques. PAS and immunohistochemistry for CD10 were performed. We observed villous atrophy with intestinal epithelial dysplasia and disorganization on the surface of epithelial cells resembling tufts in jejunal and ileal tissue. The objective of this study was to present a rare case of neonatal enteropathy, especially TE, describe the methodology used to study the biopsy, and discuss the differential diagnoses. TE is a rare neonatal enteropathy that is difficult to diagnose and manage. Children in whom TE is suspected should be referred to specialized pediatric centers, with the option of intestinal transplantation.


Subject(s)
Diarrhea, Infantile/pathology , Malabsorption Syndromes/pathology , Diagnosis, Differential , Diarrhea, Infantile/surgery , Fatal Outcome , Humans , Infant , Malabsorption Syndromes/surgery , Male
13.
An Pediatr (Barc) ; 83(3): 160-5, 2015 Sep.
Article in Spanish | MEDLINE | ID: mdl-25547668

ABSTRACT

INTRODUCTION: Microvillous inclusion disease is a rare autosomal recessive condition, characterized by severe secretory diarrhea that produces a permanent intestinal failure and dependency on parenteral nutrition. It usually begins in the neonatal period, and the only treatment at present is intestinal transplantation. PATIENTS AND METHODS: A retrospective review was conducted on 6 patients (three males and three females) diagnosed with microvillous inclusion disease between 1998 and 2013. RESULTS: All debuted in the first month of life, with a median age of three days (range, 3-30 days), and had secretory diarrhea dependent on parenteral nutrition, with fasting fecal volume of 150-200ml/kg/day. Light microscopy of duodenal biopsy samples showed varying degrees of villous atrophy without cryptic hyperplasia, accumulation of PAS positive material in the cytoplasm of enterocytes brush border, and anti-CD10 immunostaining was suggestive of intracytoplasmic inclusions. Diagnostic confirmation was performed with electron microscopy. Two of them had a genetic study, and showed mutations in MYO5B gene. Three died and three are alive; two of them with an intestinal transplantation and the third waiting for a multivisceral transplantation.


Subject(s)
Intestines/transplantation , Malabsorption Syndromes/complications , Malabsorption Syndromes/surgery , Microvilli/pathology , Mucolipidoses/complications , Mucolipidoses/surgery , Female , Humans , Infant, Newborn , Intestinal Diseases/etiology , Male , Parenteral Nutrition , Retrospective Studies
14.
Curr Opin Gastroenterol ; 29(2): 153-8, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23380574

ABSTRACT

PURPOSE OF REVIEW: Recent studies have evaluated intestinal physiology following bowel resection; understanding changes in small bowel physiology after intestinal transplantation has received less attention. In this review, we will examine recent studies focused on changes in intestinal physiology following resection and intestinal transplantation. RECENT FINDINGS: Absorption, immunity, and motility are fundamental components of small bowel physiology. Absorption after resection or transplantation is mediated by adaptation and enterocyte function. After resection, adaptation results in increased villus height and crypt depth. Hepatocyte growth factor and epidermal growth factors cause enterocyte hypertrophy and hyperplasia, allowing greater peptide uptake. Little is known about intestinal adaptation after transplant, but enteral autonomy is attainable. Immunity in small bowel after transplantation relies on a balance of innate and adaptive immune responses in the presence of the luminal microbiota. Intraepithelial lymphocytes are decreased following small bowel resection. After small bowel transplant, the number and the ratio of intraepithelial lymphocytes to enterocytes, as well as changes in the microbiota, can be used to identify rejection. After intestinal transplant, immune-mediated dysmotility is common. Perioperative infliximab in addition to tacrolimus may decrease the inflammation that contributes to dysmotility. SUMMARY: As intestinal transplantation becomes more successful, understanding how absorption, immunity, and motility changes will allow for optimization of bowel function.


Subject(s)
Intestine, Small/physiopathology , Malabsorption Syndromes/surgery , Adaptation, Physiological/physiology , Adaptive Immunity , Gastrointestinal Motility/physiology , Humans , Immunity, Innate , Intestinal Absorption/physiology , Intestine, Small/immunology , Intestine, Small/surgery , Intestine, Small/transplantation , Postoperative Period , Short Bowel Syndrome/surgery
15.
Obes Surg ; 23(4): 486-93, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23150206

ABSTRACT

BACKGROUND: Malabsorptive surgical procedures lead to deficiencies in fat-soluble vitamins. However, results concerning serum vitamin D (25OHD) after gastric bypass (GBP) are controversial. The aim of the study was to assess the influence of GBP on 25OHD and calcium metabolism. METHODS: Parameters of calcium metabolism were evaluated in 202 obese subjects before and 6 months after GBP. Thirty of them were matched for age, gender, weight, skin color, and season with 30 subjects who underwent sleeve gastrectomy (SG). A multivitamin preparation that provides 200 to 500 IU vitamin D3 per day was systematically prescribed after surgery. RESULTS: In the 202 patients after GBP, serum 25OHD significantly increased from 13.4 ± 9.1 to 22.8 ± 11.3 ng/ml (p < 0.0001), whereas parathyroid hormone (PTH) did not change. Despite a decrease in calcium intake (p < 0.0001) and urinary calcium/creatinine ratio (p = 0.015), serum calcium increased after GBP (p < 0.0001). Preoperatively, 91 % of patients had 25OHD insufficiency (< 30 ng/ml), 80% deficiency (< 20 ng/ml), and 19% secondary hyperparathyroidism (> 65 pg/ml) vs. 76, 44, and 17%, respectively, following GBP. Serum 25OHD was negatively correlated with BMI at 6 months after GBP (R = -0.299, p < 0.0001). In the two groups of 30 subjects, serum 25OHD and PTH did not differ at 6 months after GBP or SG. CONCLUSIONS: At 6 months after GBP, serum 25OHD significantly increased in subjects supplemented with multivitamins containing low doses of vitamin D. These data suggest that weight loss at 6 months after surgery has a greater influence on vitamin D status than malabsorption induced by GBP.


Subject(s)
Calcium/metabolism , Gastric Bypass/adverse effects , Malabsorption Syndromes/etiology , Malabsorption Syndromes/metabolism , Obesity, Morbid/metabolism , Vitamin D/metabolism , Weight Loss , Adult , Body Mass Index , Calcium/blood , Calcium/urine , Cohort Studies , Dietary Supplements , Female , Humans , Malabsorption Syndromes/diet therapy , Malabsorption Syndromes/surgery , Malabsorption Syndromes/urine , Male , Obesity, Morbid/blood , Obesity, Morbid/diet therapy , Obesity, Morbid/surgery , Parathyroid Hormone/blood , Prospective Studies , Time Factors , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D/urine
16.
Nutr. hosp ; 28(supl.2): 23-30, 2013.
Article in English | IBECS | ID: ibc-117145

ABSTRACT

Diabetes mellitus (DM) is a public health problem with a prevalence of 345 million people worldwide that it may double by the year 2030 and have a high costs and mortality. Gastrointestinal surgery is accepted as a form of treatment that was already suggested for obese in 1987 by Pories, confirmed for obese patients by the meta-analysis of Buchwald and the direct comparison of gastric bypass with medical treatment in the study of Schauer that demonstrate a 4 fold greater resolution rate of DM with surgery. Improvement occurs immediately after surgery, before the patients lose weight in with BMI > 35; but there is doubt if the existent evidence is enough to extrapolate these results to patients with BMI < 35 and especially with BMI < 30, in spite that four reviews in patients with this BMI and DM2 demonstrated the same results when stomach, duodenum and part of jejunum is bypassed as happen gastric bypass (better results with this of one anastomosis than of two anastomosis, Rouxen-Y) BPD. For patients with a BMI between 30 and 35 restrictive techniques: LAGB and SGL are good but not better than the mixed: RYGB, BAGUA, or SG-DJB with remission from 60 to 100%, minor in the derivative: BPD and above on the IID with a 81% of remission. There are no differences in the metabolic control in comparison to the obese, It is progressively better with DJB, SDS, IID and BAGUA especially in patients who do not require insulin, have less time with disease, have normal C peptide levels, and not so much relation with the initial BMI that is only important to decide the degree of restriction. Although several mechanisms has been suggesed for explaining these results such as caloric intake, hormonal changes, bypass of the anterior or early stimulation of posterior intestine, fundectomy, intestinal gluconeogenesis and others, new ones will appear in the near future (AU)


La diabetes mellitus (DM) es un problema de salud pública, con una prevalencia de 345 millones de personas, que puede duplicarse para el año 2030 y con importante repercusión en costes y mortalidad. La cirugía gastrointestinal es aceptada como una forma de tratamiento sugerida en obesos desde 1987 por Pories, y confirmada por el meta-análisis de Buchwald y la comparación directa del bypass gástrico con el mejor tratamiento médico en el estudio de Schauer que pone de manifiesto un índice de remisión 4 veces mayor con la cirugía. La mejoría ocurre inmediatamente después de la cirugía, antes de la pérdida de peso en pacientes con IMC > 35; pero hay duda si la evidencia existente es suficiente para extrapolar estos resultados a pacientes con IMC < 35 y especialmente con IMC < 30, a pesar de existir cuatro revisiones en pacientes con este IMC y DM2 que demuestran los mismos resultados que en obesos cuando se puentea estómago, duodeno y parte del yeyuno como pasa en el bypass gástrico y la DBP. Para pacientes con IMC entre 30 y 35 las técnicas restrictivas: BGAL Y GVL son buenas pero no superiores a las mixtas: BGYR, BAGUA o GV-BDY con remisión desde 60 a 100%, menor en las derivativas: DBP y mayor en la IID con un 81% de remisión. En pacientes con sobrepeso no existen diferencias en el control metabólico respecto a los obesos. Es progresivamente mejor con DBP, CDC, IID y BAGUA sobre todo en pacientes que no requieren insulina, tienen menos tiempo con la enfermedad o con un nivel de peptido C normal, factores determinantes y no así el IMC inicial que sólo influye en el volumen de restricción. Aunque se han sugerido distintos mecanismos para explicar los resultados como ingesta calórica, hormonales, teoría del intestino anterior o posterior, fundectomía , neoglucogénesis intestinal y otros, aparecerán más en un futuro no lejano (AU)


Subject(s)
Humans , Diabetes Mellitus, Type 2/surgery , Obesity/surgery , Bariatric Surgery , Body Mass Index , Malabsorption Syndromes/surgery
17.
J Visc Surg ; 149(6): 380-4, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23142400

ABSTRACT

Intestinal transplantation (IT) can involve small bowel transplantation alone, or be associated with liver or multivisceral transplantation. Although IT is the radical treatment for intestinal failure, home parenteral nutrition (PN) remains the treatment of choice for this disease. Indications for IT are still debated. A recent study showed that early referral for IT is recommended for patients with life-threatening combined liver and intestinal failure or for patients with invasive intra-abdominal desmoid tumors. In the same study, no survival benefit was shown for patients undergoing IT for ultra-short bowel or major complications related to the PN catheter; indications still need to be fully assessed. While short-term outcomes for IT have improved dramatically (one-year survival for small bowel-alone IT is now 80% versus 0-28% in the 1980s), long-term outcomes have not improved much since the introduction of Tacrolimus in the 1990s: five-year survival still does not exceed 60%. Some prospective developments could improve these results: the use of multivisceral grafts, the use of Sirolimus and Thymoglobulins in the immunosuppressive treatment, or the use of new biochemical markers for early diagnosis of graft rejection.


Subject(s)
Intestine, Small/transplantation , Malabsorption Syndromes/surgery , Graft Rejection/diagnosis , Graft Rejection/mortality , Graft Rejection/prevention & control , Graft Survival , Humans , Immunosuppressive Agents/therapeutic use , Malabsorption Syndromes/etiology , Malabsorption Syndromes/mortality , Malabsorption Syndromes/therapy , Parenteral Nutrition, Total , Short Bowel Syndrome/etiology , Short Bowel Syndrome/mortality , Short Bowel Syndrome/surgery , Short Bowel Syndrome/therapy , Treatment Outcome
18.
Obes Surg ; 22(12): 1909-15, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23001573

ABSTRACT

Longitudinal sleeve gastrectomy (LSG) has been validated for the treatment of morbid obesity. However, treatment failures can appear several months after SG. Additional malabsorptive surgery is generally recommended in such cases. The objective of the present study was to evaluate the outcomes of repeat SG (re-SG) relative to first-line SG. This was a retrospective study included 15 patients underwent re-SG after failure of first-line SG (i.e. University Hospital, France; Public Practice). These patients were matched (for age, gender, body mass index and comorbidities) 1:2 with 30 patients having undergone first-line SG. The efficacy criteria comprised intra-operative data and postoperative data. The overall study population comprised 45 patients. The re-SG and first-line SG groups did not differ significantly in terms of median age (p = NS). The median BMI was similar in the two groups (43 kg/m(2) vs. 42.3 kg/m(2), p = NS). The two groups were similar in terms of the prevalence of comorbidities. The mean operating time was longer in the re-SG group (116 vs. 86 min; p ≤ 0.01). The postoperative complication rate was twice as high in the re-SG group (p = 0.31). Two patients in the re-SG group developed a gastric fistula (p = 0.25) and one of the latter died. At 12 months, the Excess Weight Loss was 66% (re-SG group) and 77% (first-line SG group) (p = 0.05). Re-SG is feasible but appears to be associated with a greater risk of complications. Nevertheless, re-SG can produce results (in terms of weight loss), equivalent to those obtained after first-line SG.


Subject(s)
Digestive System Fistula/surgery , Gastroplasty , Malabsorption Syndromes/surgery , Obesity, Morbid/surgery , Postoperative Complications/surgery , Adult , Aged , Body Mass Index , Case-Control Studies , Digestive System Fistula/epidemiology , Female , Follow-Up Studies , France/epidemiology , Gastroplasty/adverse effects , Gastroplasty/methods , Humans , Malabsorption Syndromes/epidemiology , Male , Middle Aged , Obesity, Morbid/epidemiology , Postoperative Complications/epidemiology , Reoperation/methods , Retrospective Studies , Treatment Outcome , Weight Loss
19.
Dig Dis ; 30(2): 187-95, 2012.
Article in English | MEDLINE | ID: mdl-22722437

ABSTRACT

Given the emerging role of endoscopic procedures in the treatment of obesity and rapid changes in endoscopic technologies and techniques, this review considers the current state of endoscopic management of obesity. Endoluminal interventions performed entirely through the GI tract by using flexible endoscopy offer the potential for an ambulatory weight loss procedure that may be safer and more cost- effective compared with current surgical approaches. Endoscopic techniques attempt to mimic the anatomic features of bariatric surgery. Accordingly, there are two main endoscopic weight loss modalities - restrictive and malabsorptive. Restrictive procedures act to decrease gastric volume by space-occupying prosthesis and/or by suturing or stapling devices, while malabsorptive procedures tend to create malabsorption by preventing food contact with the duodenum and proximal jejunum. The former include intragastric balloon treatment, endoluminal vertical gastroplasty, transoral gastroplasty and transoral endoscopic restrictive implant system, while the latter include duodenojejunal bypass sleeve. Gastroduodenojejunal bypass sleeve is a combination of both procedures. Except for intragastric balloon, all mentioned procedures are rather new, tested on a small number of human subjects, with a high rate of success, but with limited knowledge on safety and long-term efficacy. The role of gastric electrical stimulation and intragastric injections of botulinum toxin in obesity treatment is also considered as is the role of minimally invasive bariatric endoscopic interventions.


Subject(s)
Endoscopy/methods , Obesity/surgery , Electric Stimulation , Gastric Balloon , Humans , Malabsorption Syndromes/surgery , Natural Orifice Endoscopic Surgery
20.
J Pediatr Surg ; 46(12): 2376-82, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22152886

ABSTRACT

Microvillous inclusion disease is a congenital intestinal epithelial cell disorder leading to lifelong intestinal failure. In this report, we discuss the use of a fish oil-based lipid emulsion in the treatment of 3 patients with microvillous inclusion disease who developed parenteral nutrition-associated liver disease.


Subject(s)
Cholestasis/therapy , Fat Emulsions, Intravenous/therapeutic use , Fish Oils/therapeutic use , Malabsorption Syndromes/therapy , Mucolipidoses/therapy , Parenteral Nutrition/adverse effects , Phospholipids/adverse effects , Postoperative Complications/therapy , Soybean Oil/adverse effects , Amino Acids/therapeutic use , Bilirubin/blood , Breast Feeding , C-Reactive Protein/analysis , Child, Preschool , Cholestasis/blood , Cholestasis/etiology , Diarrhea, Infantile/etiology , Diarrhea, Infantile/therapy , Electrolytes/therapeutic use , Emulsions/adverse effects , Fat Emulsions, Intravenous/adverse effects , Glucose/therapeutic use , Humans , Inclusion Bodies , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/surgery , Intestines/transplantation , Liver Diseases/etiology , Liver Diseases/therapy , Malabsorption Syndromes/complications , Malabsorption Syndromes/surgery , Male , Microvilli/pathology , Mucolipidoses/complications , Mucolipidoses/surgery , Parenteral Nutrition Solutions/therapeutic use , Postoperative Complications/blood , Postoperative Complications/etiology , Solutions/therapeutic use , Transplantation, Homologous , Triglycerides
SELECTION OF CITATIONS
SEARCH DETAIL
...